proline has been researched along with cytidine in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (32.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 14 (56.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kulonen, E; Potila, M | 2 |
| Rönnemaa, T | 1 |
| Bentley-Phillips, C; Marks, R | 1 |
| Ahonen, J; Mobacken, H; Zederfeldt, B | 1 |
| Rantanen, J | 1 |
| Andreeva, IS; Poslovina, AS; Salganik, RI; Vasjunina, EA | 1 |
| Stiller, KJ | 1 |
| Asai, Y; Homma, M; Sato, K; Yorimitsu, T | 1 |
| Sulkowski, MS | 1 |
| Kronenberger, B; Zeuzem, S | 1 |
| Couzin-Frankel, J | 1 |
| Parums, DV | 2 |
| Borio, LL; Bright, RA; Emanuel, EJ | 1 |
| Del Rio, C; Gandhi, RT; Malani, PN | 1 |
| Misra, A; Singh, A; Singh, AK; Singh, R | 1 |
| Kozlov, M | 1 |
| André, E; Chiu, W; De Jonghe, S; Jochmans, D; Leyssen, P; Maes, P; Neyts, J; Raymenants, J; Slechten, B; Vangeel, L | 1 |
| Bajaj, SS; Stanford, FC | 1 |
| Chen, C; Cheng, Y; Feng, Z; Mao, Q; Tang, J; Wang, C; Wang, M; Wen, W; Wu, Q; Zhang, X; Zhou, M; Zhou, X | 1 |
| Ledford, H | 1 |
| Adachi, E; Chong, Z; Diamond, MS; Douek, DC; Duong, C; Fujisaki, S; Furusawa, Y; Godbole, S; Gordon, A; Hagihara, M; Halfmann, PJ; Hasegawa, H; Hattori, SI; Hojo, M; Iida, S; Imai, M; Ito, M; Iwatsuki-Horimoto, K; Kawaoka, Y; Kiso, M; Koga, M; Kuroda, M; Larson, D; Li, R; Liu, Y; Loeber, S; Maeda, K; Maemura, T; Mitamura, K; Mitsuya, H; Murakami, J; Ohmagari, N; Okuda, M; Ozono, S; Saito, M; Sakai-Tagawa, Y; Sato, T; Suzuki, T; Takashita, E; Tsutsumi, T; Ueki, H; Ujie, M; Uraki, R; Valdez, R; Wang, Z; Watanabe, S; Wright, R; Yamamoto, S; Yamayoshi, S; Yasuhara, A; Yotsuyanagi, H | 1 |
3 review(s) available for proline and cytidine
| Article | Year |
|---|---|
Specific targeted antiviral therapy for hepatitis C.
Topics: Antiviral Agents; Benzofurans; Clinical Trials as Topic; Cytidine; Hepatitis C; Humans; Prodrugs; Proline; Protease Inhibitors; RNA-Dependent RNA Polymerase | 2007 |
Future treatment options for HCV: double, triple, what is the optimal combination?
Topics: Antiviral Agents; Cytidine; DNA-Directed RNA Polymerases; Drug Delivery Systems; Drug Resistance, Viral; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Nucleosides; Oligopeptides; Polyethylene Glycols; Prodrugs; Proline; Protease Inhibitors; Pyrimidine Nucleosides; Recombinant Proteins; Ribavirin | 2008 |
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Fluvoxamine; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2 | 2022 |
1 trial(s) available for proline and cytidine
| Article | Year |
|---|---|
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
Topics: Adenosine Monophosphate; Aged; Alanine; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Double-Blind Method; Drug Approval; Drug Combinations; Female; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Male; Middle Aged; Nitriles; Proline; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome | 2022 |
21 other study(ies) available for proline and cytidine
| Article | Year |
|---|---|
Effects of antirheumatic drugs on sponge-induced granulation tissue, rheumatoid synovial tissue, matrix-free tendon cells and fibroblast plasma membranes in vitro.
Topics: Animals; Anti-Inflammatory Agents; Cell Membrane; Collagen; Cytidine; DNA; Fibroblasts; Glycosaminoglycans; Granulation Tissue; In Vitro Techniques; Proline; Protein Biosynthesis; Rats; Rheumatic Diseases; Synovial Membrane; Tendons | 1975 |
Effect of high cholesterol, olive oil diet on the lipids and connective tissue in rat liver. A biochemical study.
Topics: Animals; Body Weight; Cholesterol; Cholesterol, Dietary; Collagen; Connective Tissue; Cytidine; Dietary Fats; DNA; Fatty Liver; Glycosaminoglycans; Hexosamines; Hydroxyproline; Lipid Metabolism; Lipids; Liver; Nitrogen; Oils; Organ Size; Proline; Rats; RNA; Time Factors | 1976 |
Effect of the administration of antirheumatic drugs on experimental granuloma in rat.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Cellulose; Cytidine; Granuloma; Hexosamines; Hydroxyproline; Indomethacin; Male; Nitrogen; Nucleic Acids; Phenylbutazone; Prednisolone; Proline; Rats; Sulfates; Uronic Acids | 1975 |
Cell division and metabolic activity of naevus cells. The relationships between anatomy and behaviour in moles.
Topics: Culture Techniques; Cytidine; DNA; Humans; Mitosis; Nevus, Pigmented; Proline; Skin Neoplasms; Thymidine | 1976 |
The effect of cationic triphenylmethane dye (crystal violet) on rabbit granulation tissue. Oxygen consumption and RNA and protein synthesis in tissue slices.
Topics: Animals; Carbon Radioisotopes; Collagen; Cytidine; Depression, Chemical; Female; Gentian Violet; Granulation Tissue; Hydroxyproline; In Vitro Techniques; Oxygen Consumption; Proline; Protein Biosynthesis; Rabbits; RNA; Time Factors; Tritium | 1974 |
Radiation injury of connective tissue. A biochemical investigation with experimental granuloma.
Topics: Animals; Cell Division; Collagen; Connective Tissue; Connective Tissue Cells; Cytidine; DNA; Dose-Response Relationship, Radiation; Granulation Tissue; Granuloma; Hemoglobins; Hexosamines; Hydroxyproline; Nitrogen; Proline; Radiation Effects; Radiation Injuries, Experimental; Rats; RNA; Solubility; Sulfates; Thymidine; Time Factors; Tritium; Wound Healing | 1973 |
Mutagenic action of N4-hydroxycytidine on Escherichia coli B cyt-.
Topics: Arginine; Cell Division; Cytidine; Escherichia coli; Hydroxylation; Mutagens; Mutation; Proline | 1973 |
Problems of in-vitro incubation with radioactive precursors.
Topics: Animals; Antineoplastic Agents; Cytidine; Humans; Neoplasms; Phenylalanine; Proline; Rats; Thymidine; Tritium | 1973 |
Intermolecular cross-linking between the periplasmic Loop3-4 regions of PomA, a component of the Na+-driven flagellar motor of Vibrio alginolyticus.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Copper; Cross-Linking Reagents; Cytidine; Dithiothreitol; DNA Primers; Ions; Kanamycin; Mutagenesis, Site-Directed; Periplasm; Proline; Protein Conformation; Protein Structure, Secondary; Protein Structure, Tertiary; Sodium; Structure-Activity Relationship; Time Factors; Vibrio | 2000 |
Antiviral pills could change pandemic's course.
Topics: Antiviral Agents; Clinical Trials as Topic; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2; Tablets | 2021 |
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
Topics: Administration, Oral; Antibodies, Monoclonal; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Approval; Drug Repositioning; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2; United States; United States Food and Drug Administration | 2022 |
A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; COVID-19 Vaccines; Cytidine; Drug Combinations; Endemic Diseases; Humans; Hydroxylamines; Immunization Schedule; Lactams; Leucine; Nitriles; Population Surveillance; Proline; Ritonavir; SARS-CoV-2; United States | 2022 |
COVID is here to stay: countries must decide how to adapt.
Topics: Adaptation, Psychological; Adult; Child; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Combinations; Endemic Diseases; Humans; Hydroxylamines; Immunity, Herd; Immunization, Secondary; International Cooperation; Lactams; Leucine; Nitriles; Physical Distancing; Proline; Reinfection; Ritonavir; SARS-CoV-2; Social Change; South Africa | 2022 |
COVID-19 Therapeutics for Nonhospitalized Patients.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; Child; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Female; Health Care Rationing; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Outpatients; Pregnancy; Proline; Ritonavir | 2022 |
Why scientists are racing to develop more COVID antivirals.
Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Combinations; Drug Development; Drug Resistance, Viral; Drug Therapy, Combination; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Medication Adherence; Molecular Targeted Therapy; Mutagenesis; Nitriles; Proline; Public-Private Sector Partnerships; Research Personnel; Ritonavir; SARS-CoV-2 | 2022 |
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
Topics: Adenosine; Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Cytidine; Humans; Hydroxylamines; Lactams; Leucine; Microbial Sensitivity Tests; Nitriles; Proline; RNA-Dependent RNA Polymerase; SARS-CoV-2; Vero Cells; Virus Replication | 2022 |
COVID-19: LMICs need antivirals as well as vaccines.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Developed Countries; Developing Countries; Drug Costs; Healthcare Disparities; Hospitalization; Humans; Hydroxylamines; Lactams; Leucine; Licensure; Nitriles; Proline | 2022 |
Treatment of COVID-19 in high-risk outpatients.
Topics: Adenosine Monophosphate; Alanine; Ambulatory Care; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Outpatients; Proline; Ritonavir; Treatment Outcome | 2022 |
Hundreds of COVID trials could provide a deluge of new drugs.
Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Depsipeptides; Dexamethasone; Drug Combinations; Drug Repositioning; Drug Synergism; Esters; Guanidines; Hospitalization; Host-Pathogen Interactions; Humans; Hydroxylamines; Internationality; Lactams; Leucine; Mice; National Institutes of Health (U.S.); Nitriles; Peptide Elongation Factor 1; Peptides, Cyclic; Proline; Protease Inhibitors; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Serine Endopeptidases; Sodium-Glucose Transporter 2 Inhibitors; United States; Virus Replication | 2022 |
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cricetinae; Cytidine; Drug Combinations; Hydroxylamines; Indazoles; Lactams; Leucine; Mice; Nitriles; Proline; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Triazines; Triazoles | 2022 |
Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Drug Combinations; Humans; Hydroxylamines; Lactams; Leucine; Nitriles; Proline; Ritonavir; SARS-CoV-2 | 2022 |